
TCN boosts power supply in Lekki with new 75MVA transformerJOHANNESBURG, South Africa – Former ANC president and current Umkhonto weSizwe (MK) party founder Jacob Zuma has finally been expelled from the organisation he once led. This after ANC’s national disciplinary committee of appeal upheld the decision of the party’s national disciplinary appeal to expel Zuma from the party. Zuma launched the breakaway party last December while claiming to still be a member of the ANC, a strategy which paid off at the polls on 29 May when MK party took 14% of the vote — and the parliamentary majority the ANC had held since 1994. Zuma was suspended and charged in terms of the ANC’s constitution, with the committee finding against him and expelling him last month, a decision which he appealed. ANC spokesperson Mahlengi Bhengu-Motsiri said in a statement on Friday afternoon that Zuma’s behaviour had been the “highest form of ill-discipline” and had been a “direct attack on the historical mission of the ANC”. “By establishing and leading a rival political party, he abandoned the core values of organisational loyalty and collective accountability, converting himself into a tool for destabilisation,” she said. “As a former president of the ANC, Mr Zuma was expected to embody the highest standards of disciplined leadership and advanced cadres who serve as guides and inspiration for all members of our movement and society. “Instead, his actions have undermined the unity and cohesion of the movement at a time when it is critical to consolidate and push forward with organisational renewal and confront the pressing challenges facing South Africa,” she said. Zuma’s “severe breach” of the ANC’s organisational discipline had necessitated his expulsion to safeguard its integrity and unity. The ANC will never permit an individual, regardless of stature or historical contribution, to undermine its mission to build a non-racial, non-sexist, democratic and prosperous society,” Bhengu-Motsiri said. She said the expulsion reaffirmed the ANC’s commitment to revolutionary morality and discipline and to democratic centralism. “This decision must serve as a reminder that no individual is greater than the movement, and that the ANC strength lies in its collective leadership and unwavering dedication to the aspirations of the people,” she said. Zuma, who served two terms as ANC president and president of the country until his recall by the party in February 2018, has argued that he remains a party member and that his formation of the MK party is aimed at “saving” it from its current leadership. This despite the fact that the MK party is the official opposition in parliament and in KwaZulu-Natal. MK party spokesperson Nhlamulo Ndhlela did not respond to a request for comment from the Mail & Guardian. Mail & Guardian
D.C. Dispatch: Miller-Meeks calls for PBM reform, Ernst and Grassley prepare for Trump nomineesWith Trump on the way, advocates look to states to pick up medical debt fight
PLAINS, Ga. — Jimmy Carter, the 39th President of the United States and a Nobel Peace Prize winner whose post-White House life was steeped in fighting for human rights and personally helping build homes through Habitat for Humanity, has died. He was 100. Carter passed away Sunday afternoon in Plains, Georgia, The Carter Center announced . The organization shared in Feb. 2023 that the former president had entered home hospice care. A few months later, the family shared that former first lady Rosalynn Carter was diagnosed with dementia. She passed away in November 2023. While family members have since shared they didn’t expect the former president to go on much longer after Rosalynn’s death, Carter defied expectations and on Oct. 1 became the first U.S. president to live a full century. James Earl Carter, Jr. was born in Plains, Georgia, on Oct. 1, 1924. Peanut farming and devotion to the Baptist Church were mainstays of his upbringing. After graduating from the Naval Academy in 1946, Carter went on to marry Rosalynn Smith. After he served seven years as a naval officer, Carter returned to Plains. He first entered the political world in 1962, serving two terms in the Georgia state senate. Eight years later, Carter was elected governor of Georgia, and held that office from 1971 to 1975. Carter was the Democratic nominee for president in 1976 and went on to defeat incumbent Pres. Gerald Ford in the general election, 297 electoral votes to 240. Carter is the last Democratic presidential nominee to win the states of Alabama, Mississippi and Texas. “I would hope that the nations of the world might say that we had built a lasting peace, based not on weapons of war, but on international policies that reflect our own most precious values,” Carter said in his inaugural address. Among his accomplishments in the Oval Office, Carter helped calm tensions in the Middle East as he facilitated the Camp David Accords, signed by Egyptian President Anwar Sadat and Israeli Prime Minister Menachem Begin in 1978. Carter also created two new cabinet-level departments – the Department of Energy and the Department of Education. But there were controversies, particularly in the final 14 months of his presidency. The Iran Hostage Crisis saw 66 American diplomats and citizens held hostage in the U.S. Embassy in Iran. In an attempt to free the hostages, Carter ordered a military operation that failed, killing eight American servicemen. After 444 days, the hostages were freed on January 20, 1981 -- the day Carter's successor, Ronald Reagan, took office. Carter also ordered a U.S. boycott of the 1980 Summer Olympic Games in Moscow to protest the Soviet Union invading Afghanistan. Sixty other nations also boycotted. The Soviets would return the gesture by boycotting the 1984 Olympics in Los Angeles. Carter lost a bid for a second term to Reagan in what was both an electoral vote and popular vote landslide . After leaving Washington, Carter’s spent his time advancing human rights around the world. In 1982, he established The Carter Center in Atlanta. “I’ve been humbled to get to know people around the world and to see that, in effect, all people on earth are the same in the eyes of God, and should be the same in the eyes of each other – worthy of respect, care and love,” Carter said. His work abroad won him the 2002 Nobel Peace Prize. Carter also continued to give back at home through his involvement with Habitat for Humanity. He also taught Sunday school and was a deacon at the Maranatha Baptist Church of Plains. "We can choose to alleviate suffering. We can choose to work together for peace. We can make these changes — and we must," Carter once said. Carter holds the distinction of living longer than any other former president. He and wife, Rosalynn, also hold the record of the longest-married couple in presidential history – with the couple celebrating their 77th wedding anniversary on July 7, 2023. Carter is survived by three sons, one daughter, 11 grandchildren and 14 great-grandchildren. Next up in 5 Example video title will go here for this video Next up in 5 Example video title will go here for this video
The semiconductor industry is experiencing a shakeup, with Taiwan Semiconductor Manufacturing Company (TSMC) and ASML at the center of attention. TSMC , the undisputed leader in semiconductor contract manufacturing, saw its stock soar over 90% this year due to the proliferation of chips and rising demand for AI technology. TSMC’s role as a vital partner for tech giants like Apple and Nvidia has strengthened its market position significantly. ASML , maker of the highly sought-after extreme ultraviolet (EUV) lithography machines used by TSMC and other industry titans, experienced a modest 5% decline in stock value in 2024. This downturn hasn’t diminished ASML’s pivotal role, as almost half its revenue this year arose from strategic dealings with China, despite export restrictions. TSMC’s thrived amid a booming demand for advanced chips, reporting impressive revenue growth of 36% in the third quarter of this year. The company’s ability to enforce significant pricing power has also bolstered its profits, predicting a promising outlook for 2025 as new fab operations in Japan ramp up production. Conversely, ASML faces a transitional phase as it advances its high-NA EUV technology. While negotiations with TSMC over high equipment prices have been ongoing, the first deliveries are set to occur by year-end, signaling a potential market rebound. Despite ASML’s challenges, its near monopoly on high-end chipmaking technology positions it favorably for long-term growth. Both companies present compelling opportunities for investors in 2025, with TSMC currently offering a more attractive valuation. Nonetheless, industry watchers could benefit from considering stakes in both semiconductor giants. Will TSMC and ASML Continue to Dominate the Semiconductor Industry in 2025? The semiconductor sector is experiencing a dynamic transformation, with companies like Taiwan Semiconductor Manufacturing Company (TSMC) and ASML leading the charge. As 2025 approaches, the market is focusing on potential industry trends, strategic moves, and the impacts of geopolitical factors on these key players. Market Analysis: TSMC’s Strategic Position TSMC has reinforced its stature as a cornerstone in semiconductor manufacturing due to substantial hikes in both demand and stock performance, specifically a 90% rise in its shares this year. This surge can be credited to its pivotal role in catering to tech behemoths such as Apple and Nvidia. The company’s impressive growth, notably a 36% increase in revenue in the third quarter, indicates a prosperous horizon. TSMC is expanding its fabrication operations to Japan, which is likely to enhance its production capacity and market share. ASML’s Technology: A Double-Edged Sword ASML, known for its unparalleled extreme ultraviolet (EUV) lithography technology, faces interesting prospects and challenges. Their stock experienced a 5% contraction in 2024; however, the company’s strategic involvement with China, comprising nearly half of its revenue, underscores its global influence despite ongoing export regulations. Additionally, the rollout of advanced high-NA EUV tools promises technological edge, albeit at higher negotiation costs with clients like TSMC. Innovations and Predictions: What’s Next? Key innovations such as the further development of high-NA EUV technology could redefine the chipmaking landscape. If successful, ASML’s dedication to technology advancement may trigger newfound growth opportunities. By delivering the first units by the end of the year, ASML is setting expectations for a market resurgence and cementing its status as a technological leader. Investment Considerations: The Pros and Cons – Pros : TSMC’s robust market position and ongoing expansion efforts make it an enticing prospect for investors. Its price agility and leading manufacturing capabilities cater to the accelerating AI demand, while ASML’s near-monopolistic hold on EUV technology secures its long-term potential. – Cons : Both companies face hurdles such as geopolitical tensions and evolving technological demands, which could temper growth. ASML’s stock contraction and the high costs of pioneering tech development present short-term challenges. Trends and Insights: Navigating Future Prospects As we look towards 2025, TSMC and ASML symbolize both resilience and adaptation within the semiconductor domain. These entities are expected to leverage their technological assets amidst a landscape rife with competition and innovation. For market enthusiasts, a balanced portfolio that includes stakes in both might provide a hedge against industry volatility. For further information on TSMC and ASML’s role in the semiconductor scene, you may visit their respective websites: TSMC and ASML .
ATLANTA (AP) — Jimmy Carter, the peanut farmer who tried to restore virtue to the White House after the Watergate scandal and Vietnam War, then rebounded from a landslide defeat to become a global advocate of human rights and democracy, has died. He was 100 years old . The Carter Center said the 39th president died Sunday afternoon, more than a year after entering hospice care , at his home in Plains, Georgia, where he and his wife, Rosalynn, who died in November 2023, lived most of their lives. The center said he died peacefully, surrounded by his family. As reaction poured in from around the world, President Joe Biden mourned Carter’s death, saying the world lost an “extraordinary leader, statesman and humanitarian” and he lost a dear friend. Biden cited Carter’s compassion and moral clarity, his work to eradicate disease, forge peace, advance civil and human rights, promote free and fair elections, house the homeless and advocacy for the disadvantaged as an example for others. “To all of the young people in this nation and for anyone in search of what it means to live a life of purpose and meaning – the good life – study Jimmy Carter, a man of principle, faith, and humility,” Biden said in a statement. “He showed that we are a great nation because we are a good people – decent and honorable, courageous and compassionate, humble and strong.” Biden said he is ordering a state funeral for Carter in Washington. A moderate Democrat, Carter ran for president in 1976 as a little-known Georgia governor with a broad grin, effusive Baptist faith and technocratic plans for efficient government. His promise to never deceive the American people resonated after Richard Nixon’s disgrace and U.S. defeat in southeast Asia. “If I ever lie to you, if I ever make a misleading statement, don’t vote for me. I would not deserve to be your president,” Carter said. Carter’s victory over Republican Gerald Ford, whose fortunes fell after pardoning Nixon, came amid Cold War pressures, turbulent oil markets and social upheaval over race, women’s rights and America’s role in the world. His achievements included brokering Mideast peace by keeping Egyptian President Anwar Sadat and Israeli Prime Minister Menachem Begin at Camp David for 13 days in 1978. But his coalition splintered under double-digit inflation and the 444-day hostage crisis in Iran. His negotiations ultimately brought all the hostages home alive, but in a final insult, Iran didn’t release them until the inauguration of Ronald Reagan, who had trounced him in the 1980 election. Humbled and back home in Georgia, Carter said his faith demanded that he keep doing whatever he could, for as long as he could, to try to make a difference. He and Rosalynn co-founded The Carter Center in 1982 and spent the next 40 years traveling the world as peacemakers, human rights advocates and champions of democracy and public health. Awarded the Nobel Peace Prize in 2002, Carter helped ease nuclear tensions in North and South Korea, avert a U.S. invasion of Haiti and negotiate cease-fires in Bosnia and Sudan. By 2022, the center had monitored at least 113 elections around the world. Carter was determined to eradicate guinea worm infections as one of many health initiatives. Swinging hammers into their 90s, the Carters built homes with Habitat for Humanity. The common observation that he was better as an ex-president rankled Carter. His allies were pleased that he lived long enough to see biographers and historians revisit his presidency and declare it more impactful than many understood at the time. Propelled in 1976 by voters in Iowa and then across the South, Carter ran a no-frills campaign. Americans were captivated by the earnest engineer, and while an election-year Playboy interview drew snickers when he said he “had looked on many women with lust. I’ve committed adultery in my heart many times,” voters tired of political cynicism found it endearing. The first family set an informal tone in the White House, carrying their own luggage, trying to silence the Marine Band’s traditional “Hail to the Chief" and enrolling daughter, Amy, in public schools. Carter was lampooned for wearing a cardigan and urging Americans to turn down their thermostats. But Carter set the stage for an economic revival and sharply reduced America's dependence on foreign oil by deregulating the energy industry along with airlines, trains and trucking. He established the departments of Energy and Education, appointed record numbers of women and nonwhites to federal posts, preserved millions of acres of Alaskan wilderness and pardoned most Vietnam draft evaders. Emphasizing human rights , he ended most support for military dictators and took on bribery by multinational corporations by signing the Foreign Corrupt Practices Act. He persuaded the Senate to ratify the Panama Canal treaties and normalized relations with China, an outgrowth of Nixon’s outreach to Beijing. But crippling turns in foreign affairs took their toll. When OPEC hiked crude prices, making drivers line up for gasoline as inflation spiked to 11%, Carter tried to encourage Americans to overcome “a crisis of confidence.” Many voters lost confidence in Carter instead after the infamous address that media dubbed his “malaise" speech, even though he never used that word. After Carter reluctantly agreed to admit the exiled Shah of Iran to the U.S. for medical treatment, the American Embassy in Tehran was overrun in 1979. Negotiations to quickly free the hostages broke down, and then eight Americans died when a top-secret military rescue attempt failed. Carter also had to reverse course on the SALT II nuclear arms treaty after the Soviets invaded Afghanistan in 1979. Though historians would later credit Carter's diplomatic efforts for hastening the end of the Cold war, Republicans labeled his soft power weak. Reagan’s “make America great again” appeals resonated, and he beat Carter in all but six states. Born Oct. 1, 1924, James Earl Carter Jr. married fellow Plains native Rosalynn Smith in 1946, the year he graduated from the Naval Academy. He brought his young family back to Plains after his father died, abandoning his Navy career, and they soon turned their ambitions to politics . Carter reached the state Senate in 1962. After rural white and Black voters elected him governor in 1970, he drew national attention by declaring that “the time for racial discrimination is over.” Carter published more than 30 books and remained influential as his center turned its democracy advocacy onto U.S. politics, monitoring an audit of Georgia’s 2020 presidential election results. After a 2015 cancer diagnosis, Carter said he felt “perfectly at ease with whatever comes.” “I’ve had a wonderful life,” he said. “I’ve had thousands of friends, I’ve had an exciting, adventurous and gratifying existence.” Sanz is a former Associated Press reporter.LG USA ANNOUNCES CREATION OF 2025 SUMMER INTERNSHIPS EXCLUSIVELY FOR RUTGERS STUDENT-ATHLETES
Demko to return to the Canuck bench against Columbus — as the backup
CARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZATM (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day). TRYNGOLZA is self-administered via an auto-injector once monthly. Experience the full interactive Multichannel News Release here: https://www.multivu.com/ionis-pharmaceuticals/9295551-en-tryngolza-olezarsen-fda-approval "Today's FDA approval of TRYNGOLZA heralds the arrival of the first-ever FCS treatment in the U.S. – a transformational moment for patients and their families. For the first time, adults with FCS can now access a treatment that substantially reduces triglycerides and the risk of debilitating and potentially life-threatening acute pancreatitis," said Brett P. Monia , Ph.D., chief executive officer, Ionis. "We are proud of our long-standing partnership with the FCS community and are grateful to the patients, families and investigators who participated in our clinical studies, enabling Ionis to make this new treatment a reality. The FDA approval of TRYNGOLZA is also a pivotal moment for Ionis, representing our evolution into a fully integrated commercial-stage biotechnology company – a goal we set out to achieve five years ago. With our rich pipeline of potentially life-changing medicines, we expect TRYNGOLZA to be the first in a steady cadence of innovative medicines we will deliver independently to people living with serious diseases." The FDA approval was based on positive data from the global, multicenter, randomized, placebo-controlled, double-blind Phase 3 Balance clinical trial in adult patients with genetically identified FCS and fasting triglyceride levels ≥880 mg/dL. In the Balance study, TRYNGOLZA 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084). Reductions from baseline to 12 months were further improved, with TRYNGOLZA achieving a placebo-adjusted 57% mean reduction in triglycerides. TRYNGOLZA also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the TRYNGOLZA group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group. TRYNGOLZA demonstrated a favorable safety profile. The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and at a >3% higher frequency than placebo) were injection site reactions (19% and 9%, respectively), decreased platelet count (12% and 4%, respectively) and arthralgia (9% and 0%, respectively). Results from the Phase 3 Balance study were previously published in The New England Journal of Medicine (NEJM). "With no treatment options previously available, we were limited to relying only on extremely strict diet and lifestyle changes as the sole preventative treatment option," said Alan Brown , M.D., FNLA, FACC, FAHA, clinical professor of medicine, Rosalind Franklin University of Medicine and Science ; Balance trial investigator. "The FDA approval of TRYNGOLZA is an important moment for people living with FCS, their families and physicians who now, for the first time, have a treatment that significantly lowers triglycerides and decreases the risk of potentially life-threatening acute pancreatitis events, as an adjunct to a low-fat diet. I am excited to have a medicine I can prescribe to my patients that has been shown to change the course of their disease." FCS is a rare, genetic, potentially life-threatening form of sHTG that prevents the body from breaking down fats and severely impairs the body's ability to remove triglycerides from the bloodstream due to an impaired function of the enzyme lipoprotein lipase (LPL). While healthy levels for adults are below 150 mg/dL, people with FCS often have triglyceride levels of more than 880 mg/dL and often have a history of pancreatitis. Those living with FCS have a high risk of potentially fatal AP, which is a painful inflammation of the pancreas, and chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS can also experience psychological and financial stress, which can significantly impact their quality of life. In the U.S., FCS is estimated to impact up to approximately 3,000 people, the vast majority of whom remain undiagnosed. "As a rare and difficult to diagnose disease, FCS has a profound impact on the lives of patients and families. Many people living with FCS have experienced severe pain their whole lives – sometimes so intense they require lengthy hospitalization stays – and struggle through life with daily fatigue, nausea, brain fog and stomach pain," said Lindsey Sutton Bryan , co-founder and co-president, FCS Foundation. "Until now, our treatment options have been limited, relying on diet alone to try to manage triglyceride levels and keep acute pancreatitis attacks at bay. For the first time, adults with FCS have seen their hope for a treatment become a reality." TRYNGOLZA will be available in the U.S. before year end. Ionis is committed to helping people access the medicines they are prescribed and will offer a suite of services designed to meet the unique needs of the FCS community through Ionis Every StepTM. As part of Ionis Every Step , patients and healthcare providers will have access to services throughout the treatment journey provided by dedicated Patient Education Managers and Ionis Every Step Case Managers, including insurance and affordability support, as well as services and resources, such as disease and nutrition education. Visit TRYNGOLZA.com for more information. TRYNGOLZA was reviewed by the FDA under Priority Review and had previously been granted Fast Track designation for the treatment of FCS, Orphan Drug designation and Breakthrough Therapy designation. Olezarsen is undergoing review in the European Union and regulatory filings in other countries are planned. Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE – for the treatment of sHTG. Olezarsen has not been reviewed or approved for the treatment of sHTG by regulatory authorities. Webcast Ionis will hold a webcast today at 6:45pm ET to discuss the FDA approval. Interested parties may access the webcast here . A webcast replay will be available for a limited time. About TRYNGOLZATM (olezarsen) TRYNGOLZATM (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). TRYNGOLZA is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. It is the only treatment currently indicated in the U.S. for FCS, a potentially life-threatening disease. For more information about TRYNGOLZA, visit TRYNGOLZA.com . IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. FCS is estimated to impact up to approximately 3,000 people in the U.S. People living with FCS are at high risk of acute pancreatitis (AP) in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has discovered and developed six marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases. Ionis has a leading pipeline in neurology, cardiology and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) , LinkedIn and Instagram . Ionis Forward-Looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of TRYNGOLZA, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2023 , and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.Ionis.com . Ionis Pharmaceuticals® and TRYNGOLZATM are trademarks of Ionis Pharmaceuticals, Inc. Ionis Investor Contact: D. Wade Walke , Ph.D. info@ionis.com 760-603-2331 Ionis Media Contact: Hayley Soffer media@ionis.com 760-603-4679 View original content: https://www.prnewswire.com/news-releases/tryngolza-olezarsen-approved-in-us-as-first-ever-treatment-for-adults-living-with-familial-chylomicronemia-syndrome-as-an-adjunct-to-diet-302336747.html SOURCE Ionis Pharmaceuticals, Inc.SAN ANTONIO (AP) — Damari Monsanto's 22 points helped UTSA defeat Southwestern Adventist 117-58 on Thursday. Monsanto added six rebounds for the Roadrunners (6-5). Sky Wicks scored 20 points while shooting 8 for 12, including 4 for 7 from beyond the arc and added eight rebounds and three steals. Amir "Primo" Spears shot 5 of 10 from the field, including 1 for 5 from 3-point range, and went 5 for 6 from the line to finish with 16 points. Domonique Wilkins and Orlando Gooden each scored 19 points for Southwestern Adventist. Jason Garcia had 13 points, four assists and two steals. Story continues below video Monsanto led his team in scoring with 16 points in the first half to help put them up 61-24 at the break. UTSA extended its lead to 87-38 during the second half, fueled by a 13-3 scoring run. Wicks scored a team-high 10 points in the second half. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Jimmy Carter, 39th US president, Nobel winner, dies at 100
Excited state dynamics unlock potential for organics LEDs and bioimagingJimmy Carter, 100, gained Nebraska admirers during and after his presidency
The wife of NHL star Johnny Gaudreau 's brother Matthew Gaudreau has given birth to their first baby, four months after the siblings were killed in a road accident . Madeline Gaudreau shared Dec. 29 that their son had arrived. " Tripp Matthew ," she wrote on Instagram , alongside a photo of herself holding the newborn's hand. "Mommy & Daddy’s world." Matthew's wife had announced her pregnancy on social media in June, two months before her husband, a minor league hockey player, and Johnny were fatally struck by a Jeep driver while riding their bikes in New Jersey . "He was born to be a dad," Madeline had said about Matthew at the brothers' memorial service in September. "The moment we found out about our son Tripp, it consumed his every day. He was downloading apps, ordering books, finding the best diaper brand, making sure I had the best vitamins and asking for tips from John." She continued, "I will never forget the tears he had in his eyes when he first heard Tripp’s heartbeat." Madeline gave birth to baby Tripp three weeks after Matthew's 30th birthday. "Happy Birthday to the best husband and father," she wrote on her Instagram Dec. 5. "The moment I met you I instantly knew you were the one. As I celebrate you today (and everyday ) I am more and more in love with you and honored to be your wife." Madeline added, "John better have friends playing all day, double stuff Oreos and a nice glass of whiskey for you. I love you and can’t wait to kiss your face again." A post shared by Madeline Gaudreau (@mogaudreau) In October, Madeline shared photos from her baby shower , which included blue balloons, including one spelling out "Baby Tripp." Among the guests was Johnny's wife Meredith Gaudreau , who had announced her pregnancy with her and the Columbus Blue Jackets left winger's third child at the siblings' memorial. Also in October, the brothers' wives, parents and other family members attended the team's special tribute to the brothers at their season opening game. As a banner bearing Johnny's name and jersey number, 13, was raised, his and Meredith's daughter Noa , 2, was seen pointing up at the rafters at Columbus’ Nationwide Arena. "Thank you to our entire Columbus Blue Jackets family for such a beautiful night celebrating our favorite guy," Meredith, who also shares son Johnny , 10 months, with her late husband, wrote on Instagram after the game. "NWA was our second home as a family and a place I still feel close to John in. I could see in Noa's eyes that she can feel it too."Jaland Lowe, Pitt charge past LSU in second half to move to 6-0
Interview with Manasvini Krishna, Founder, Boss as a Service